Memorandum of Understanding forges a new collaboration for Intellimedia and Rocky View Data Solutions

November 3rd, 2017

Intellimedia Inc. and Rocky View Data Solutions are pleased to announce a new collaboration arrangement, forged by a recently signed Memorandum of Understanding. The newly formed collaboration will focus on the further development of the At-Risk Module (ARM) within Intellimedia’s Dossier software platform.

 

Clinisys announces collaboration with Microsoft Dynamics

Clinisys EMR Inc. and Microsoft Canada collaborate to advance cloud-based electronic medical records
Minister Deron Bilous from Alberta Economic Development and Trade congratulates Clinisys EMR Inc. on alliance and welcomes Microsoft to Alberta

(Edmonton, Alberta) April 12, 2017… Clinisys EMR Inc., (Clinisys) an Edmonton-based Health Data Analytics and Electronic Medical Record (EMR) solutions provider announced today it will be working with Microsoft Canada (Microsoft) to bring cloud solutions that will benefit the patient population across Canada and allow Clinisys EMR to expand its reach across Canada, and globally.

Clinisys enables cloud-based solutions that help empower and inform doctors, nurses, and all front-line health workers so that they in turn can provide better, timely, and more effective healthcare. Through this alliance Clinisys will be able to eliminate the need for physical servers and infrastructure by levering Microsoft’s Cloud platform, Azure. This will not only help Clinisys scale and grow faster but will also provide world-class security to storing patient information while meeting regulatory compliance standards. Clinisys is also working with Microsoft Canada’s Dynamics team, leveraging the functionalities of Dynamics 365 to further evolve Clinisys’ practice management and EMR solution.

Mehadi Sayed, Clinisys President and CEO says, “We are excited to be working with a global leader and are confident that this collaboration will provide exciting opportunities to grow local talent.  It will allow us to bring innovative health ICT products to local and international markets and ultimately improve the provision of healthcare services.”

“At Microsoft, our mission is to empower every person and organization on the planet to achieve more,” said Harpreet Girn, General Manager Sales, SMB at Microsoft Canada. “We are very excited to be working with companies like Clinisys, as we are helping to digitally transform the Canadian healthcare sector and are unlocking new opportunities for better patient care.”

“The economy of the next 30 years will be very different than the economy of the last 30 years,” says Deron Bilous, Alberta Minister of Economic Development and Trade.  “Alberta businesses like Clinisys are leading the way in diversifying our economy and creating new jobs. At the same time their commitment to improving patient treatment, is making life better and healthier for Alberta families.”

“Microsoft’s investment in Clinisys demonstrates the advanced technological expertise found in our province,” says Laura Kilcrease, Alberta Innovates CEO. “Alberta Innovates is proud to support Clinisys, who has clearly shown that our investment has produced results. Alberta Innovates Entrepreneurial Investments programs are focused on producing outcomes that promote diversity in the economy and help create high skilled jobs.”

Microsoft will support Clinisys EMR Inc. to reach national and international markets through the provision of systems infrastructure and global marketing expertise. This new partnership will create growth opportunities for Clinisys, create high quality jobs in Alberta and contribute to diversification of the provincial economy.
 
-30-

For more information:   Dwayne Brunner, Media Relations Manager, Alberta Innovates,
   403.619.4556 (cell & text), Dwayne.Brunner@albertainnovates.ca

 

 

 

 

 

Meet the ATC

“It was time to move out of the kitchen,” recalls Steven Gentles, CEO of AwareBase.
He moved his information management company, then a staff of three, into the professional environment of the Advanced Technology Centre (ATC) in the Edmonton Research Park. It was an easy choice as the rent was reasonable and the building was filled with entrepreneurs experiencing the same hurdles and spurts of growth that his company would face.


The drive in to the ATC weaves through the grounds of the Edmonton Research Park, reminiscent of visiting a campus with the buildings set off the road and facing inward. The architecture of the building is sloped into the landscape, huddled into a hill, angled to catch the rays of the sunny Alberta skies. It’s a building design and location that sets the tone for the work that happens inside.


Steven Gentles describes, “There aren’t a lot of suits running around. It’s a casual place where your neighbours are going through what you’re going through. It’s a community.” Unlike the stereotypical startup, there isn’t a brick in sight. This environment has a different focus: the offices feel more like classrooms, but with the ability to concentrate and close the door. There is space to breathe, ample access to natural light, and grounds to pace when working through ideas.  And everyone nearby is on the same page, like the shared energy of studying in a library with simultaneous levels of concentration.
Within three years, AwareBase had grown from three employees to forty employees. The company moved into their own building, refocused on product development, and expanded into offices in Abbotsford, Ottawa and now has an operation in New Dehli. Gentles says, “But I wouldn’t consider it a step backward if we moved back into the ATC. We haven’t had that community since we left. I miss that.”


He continues, “To transition a pre-commercial business to an actual growing business that can employ people, grow the tax base and attract the community, is a huge challenge. It is not easily accomplished.” Jenni Salonga, Program Manager of the Edmonton Research Park, agrees. She has been based out of the Advanced Technology Centre for the last decade watching entrepreneurs grow. She summarizes, “Companies such as Awarebase provide proof that working in a business incubator is really more than just space, we have a community that fosters innovation, interaction and inspiration.” The ATC is a place to move forward, a place to put the entrepreneurial spirit to task.


The Edmonton Research Park (ERP) is part of Edmonton Economic Development and is home to more than 1,500 members at 55+ companies working in diverse fields, from biotechnology to energy. Startups and growing companies can access a variety of workspaces; on-site programs, access to soft-landing programs and personalized referrals to support and funding agencies; and facilitated access and collaboration with local, national and international communities of accelerators, science parks and incubators.

 

Nanospeed Diagnostics achieves major sales milestone

SOURCE: NanoSpeed Diagnostics Inc.

June 20, 2016 09:00 ET

NanoSpeed Diagnostics and Test4D™ Achieves Major Sales Milestone

EDMONTON, AB--(Marketwired - June 20, 2016) - NanoSpeed Diagnostics Inc. ("NanoSpeed" or the "Company") is pleased to announce that Test4D™, the world's first point-of-care test for vitamin D sufficiency, has reached sales of one million (1,000,000) tests since the product launch in 2013.

"The achievement of this milestone is both a demonstration of the strong demand for on-the-spot point of care testing, as well as the increasing recognition of the importance that vitamin D plays in our everyday health," said Dr. Seema Gupta, President & CEO of NanoSpeed. "Sales continue to grow at a record pace year-over-year as distribution demands grow for a high quality and reliable test for vitamin D."

Test4D™ is currently being sold through distributors globally based in Europe, China, India and the Philippines.

This sales milestone achievement represents record-breaking news for NanoSpeed. As the Company works to add new distributors and to develop new tests for commercialization with its partners, management continues to demonstrate a commitment to sustainable growth.

Dr. Seema Gupta continues, "As we celebrate this milestone, we have always believed it is important to thank our customers, distribution partners, employees, research and development collaborators and investors for their continued support. Additionally, we would like to thank TEC Edmonton and its Health Accelerator Program as well as our dedicated Executive-in-Residence for ongoing strategic counsel of our business development activities as we continue to grow and strengthen our company and brand."

Test4D™ is not approved for commercial use in Canada or the United States and is limited by federal law to research or investigational use only.

About NanoSpeed Diagnostics Inc.

NanoSpeed, incorporated in 2009, develops proprietary diagnostic/screening test kit platforms based on their Lateral Flow Immuno Assay and Lab-on-a-Chip technologies. These technological advancements provide patients with cost effective and reliable testing tools that will address the increasing needs of the healthcare industry, regulatory agencies and consumers. For more information please visit: www.nanospeed.ca

About Vitamin D deficiency and Test4D™

Vitamin D deficiency is a common problem in Canada, where 60% of adults have suboptimal levels of 25-OH vitamin D. Vitamin D deficiency has been associated with abnormalities in absorption of calcium, phosphorus, and bone metabolism; cardiovascular disease; diabetes; cancer; osteomalacia and osteoporosis in adults; and rickets in children. Deficient vitamin D levels are typically the result of an inadequate intake of vitamin D through sunlight, diet, or supplements, or due to malabsorptive disorders.

25-OH vitamin D levels are currently measured through laboratory testing. Over the past decade, there has been an incremental surge in the demand for vitamin D testing, resulting in increasing costs to government supported healthcare systems. An alternative to laboratory testing is Point-of-Care-Testing (POCT), medical testing that occurs outside of a clinical laboratory and near the patient. Potential advantages of POCT include reduction in errors and costs to the healthcare system, and the provision of quick clinical diagnoses.

To address the demands of vitamin D testing, NanoSpeed Diagnostics Inc. developed Test4D™, a POCT device for the qualitative detection of 25-OH Vitamin D in human blood obtained via fingertip puncture.

Test4D™ is available for commercial sale through certain distributors, or can be purchased for research purposes directly from NanoSpeed.

 

http://www.marketwired.com/press-release/nanospeed-diagnostics-and-test4d-achieves-major-sales-milestone-2135671.htm

 

 

Metabelomic Technologies signs licensing & distribution agreement

 

SOURCE: Atlantic Diagnostic Laboratories, LLC

May 04, 2016 14:45 ET

Metabolomic Technologies Inc. Signs Exclusive Licensing and Distribution Agreement With U.S. Based Atlantic Diagnostic Laboratories LLC

EDMONTON, AB--(Marketwired - May 04, 2016) - Metabolomic Technologies Inc. (MTI) has signed a multi-million dollar exclusive licensing and distribution agreement with Atlantic Diagnostic Laboratories, LLC (ADL) for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer.

Colorectal cancer is a leading cause of death in North America with over 157,000 new cases reported in 2015 alone. With early detection in the adenomatous polyp stage, this form of cancer is preventable. Currently, only 39% of colorectal cancer cases in the United States are diagnosed at an early and treatable stage resulting in a five-year survival rate of 63.5%.

The introduction of PolypDx™ hopes to change those statistics. PolypDx™ gives doctors a new tool in the prevention of colorectal cancer. In a Canadian-based clinical trial of nearly 1,000 patients, MTI's PolypDx™ demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps. Once screened, patients presenting a risk of adenomatous polyps can be directed to a colonoscopy, during which the adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer. PolypDx™ is a simple and effective test requiring only a small urine sample. Early detection and ease of use are key distinguishing factors for a screening test in the prevention of colorectal cancer.

The exclusive, three and a half year, multi-million dollar licensing and distribution agreement signed between MTI and ADL provides a valuable entry point into the U.S. market. Initially, PolypDx™ will be available across twelve eastern states through existing distribution channels with the ability to grow distribution across the United States.

"The partnership and collaboration between MTI and Atlantic Diagnostic Laboratories will provide the opportunity for patients to access a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer," said Dr. Richard Fedorak, President of MTI.

"ADL, with its extensive LC/MS/MS expertise, has long awaited a high-quality partner such as MTI," said Aaron Domenico, Chief Operating Officer of ADL. He added, "ADL is very excited to be offering the PolypDx™ non-invasive urine test."

About Metabolomic Technologies Inc. (MTI):

Metabolomic Technologies Inc. (MTI) is a privately held Canadian company based in Edmonton, Alberta. A spin-off from the University of Alberta, MTI focuses on the development of metabolomics-based diagnostic systems created from proprietary biomarker technologies. The Company's flagship product, PolypDx™, an innovative urine diagnostic test, offers a significantly higher sensitivity in detecting adenomatous polyps, a precursor to colorectal cancer (CRC). CRC is a leading cause of death in North America, but is curable if identified through early screening processes. PolypDx™ provides healthcare professionals with a tool for early screening and detection over less effective fecal-based screening methodologies considered suboptimal due to a lack of sensitivity and acceptability.

MTI is committed to developing high value diagnostic tests for the management of chronic disease. The Company received the North American Frost & Sullivan Award for Technology Innovation Leadership in 2014.

About Atlantic Diagnostic Laboratories, LLC (ADL):

Atlantic Diagnostic Laboratories, LLC (ADL) is a U.S.-based independent clinical laboratory with its headquarters in the suburbs of Philadelphia. ADL is a full-service laboratory providing microbiology, chemistry, toxicology, immunology, and virology testing used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of diseases. It has also developed niche operations based on certain types of specialized testing capabilities providing insights that empower and enable medical professionals to make better healthcare decisions. ADL is fully accredited by the College of American Pathologists (CAP) for clinical and forensic studies.

http://www.marketwired.com/press-release/-2121513.htm

ContraVir Merges with Ciclofilin Pharmaceuticals

ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals

ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals

PR Newswire

EDISON, N.J., May 31, 2016

EDISON, N.J., May 31, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into a definitive merger agreement with privately-held Ciclofilin Pharmaceuticals, Inc. pursuant to which ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments which will be allocated among the holders of Ciclofilin common stock.  The milestone payments will consist of up to an aggregate $17 million cash and up to 10% of ContraVir's issued and outstanding common stock as of the closing date of the merger, and will be paid upon the achievement of certain developmental and/or regulatory milestones related to CPI-431-32, Ciclofilin's lead development candidate. 

CPI-431-32 is a next-generation non-immunosuppressive cyclophilin inhibitor shown to have best-in-class potency against hepatitis B virus (HBV) and a significantly larger selective index compared to previously known cyclophilin inhibitors. It is anticipated that this large selective index will provide a meaningful degree of clinical utility in the treatment of chronic HBV infection.  Upon completion of the merger, Ciclofilin's Founder and CEO Robert Foster, Pharm.D., Ph.D., will join ContraVir in the role of Chief Scientific Officer, and will continue leading the development of CPI-431-32 into IND-enabling studies. 

The merger will expand and strengthen ContraVir's portfolio of complementary antiviral candidates targeting HBV, which includes CMX157, a highly potent lipid conjugate of tenofovir, currently undergoing Phase 1b/2 clinical trials.  ContraVir will remain headquartered in Edison, NJ, and will acquire Ciclofilin's R&D facilities in Edmonton, Canada.

James Sapirstein, CEO of ContraVir, stated, "Completing this strategic transaction will firmly position ContraVir as an important player in the hepatitis B space.  Similar to our clinical stage candidate CMX157, we will add to our portfolio what we believe is a superior molecule that improves significantly upon the established efficacy and safety of the class of compounds from which it is derived, thereby enhancing its clinical utility as an antiviral.  Furthermore, the mechanism of action of CPI-431-32 is complementary to CMX157, each inhibiting distinct critical steps in the viral life cycle, adding robustness to our HBV portfolio.  We look forward to completing the merger and to continuing the pre-clinical development of CPI-431-32 in preparation for potentially entering the clinic in 2017."

CPI-431-32 is a highly potent derivative of cyclosporine, yet is engineered to be non-immunosuppressive.  It selectively targets and inhibits host cellular enzymes known as cyclophilins (CyP), which are commonly recruited by HBV and other viruses as part of their normal life cycle.  CPI-431-32 blocks HBV's ability to "hijack" CyP, and has also been shown to inhibit entry of HBV into liver cells as well as reduce or eliminate production and secretion of key hepatitis B antigens (HBsAg and HBeAg).  In vivo studies also demonstrated CPI-431-32's ability to reduce liver HBV DNA without significant toxicity.  It is this optimized selective index that distinguishes CPI-431-32 and improves upon previous cyclosporine derivatives.  Cyclosporines have been used clinically for more than 30 years in the field of organ transplant and more recently have been dosed in more than 2,000 patients as a treatment for chronic hepatitis C infection.  Finally, CPI-431-32 is expected to be effective against all HBV genotypes due to the fact that it inhibits host enzymes that are common to the life cycle of all HBV sub-types.

Robert Foster, Pharm.D., Ph.D., Founder and CEO of Ciclofilin, commented, "CPI-431-32 is positioned to be the leading non-immunosuppressive cyclophilin inhibitor antiviral for the treatment of hepatitis B.  My team and I are excited to join ContraVir to accelerate development of this asset, based on ContraVir's deep understanding of HBV and clear dedication to providing needed therapies for this complex, chronic infection.  Both CPI-431-32 and CMX157 have demonstrated best-in-class potential and have the benefit of positive clinical experience using related compounds, creating a very strong hepatitis B pipeline."

The merger, which has been approved by the Board of Directors of both companies, is subject to customary closing conditions.  Following the completion of the transaction, Ciclofilin will become a wholly owned subsidiary of ContraVir. 

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir for the Hepatitis B virus.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal and bone side effects.

Forward Looking Statements
Certain statements in this press release are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. ContraVir cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the likelihood that the merger is consummated, the expected benefits of the merger and the acquisition by ContraVir of Ciclofilin, challenges to intellectual property, the potential achievement of any milestones, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect ContraVir's operations is set forth in ContraVir's Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 25, 2015. ContraVir undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

For further information, please contact:

Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/contravir-to-expand-hepatitis-b-portfolio-through-strategic-merger-agreement-with-ciclofilin-pharmaceuticals-300276699.html

SOURCE ContraVir Pharmaceuticals, Inc.